International Journal of Pharmaceutics, Journal Year: 2023, Volume and Issue: 639, P. 122965 - 122965
Published: April 20, 2023
Language: Английский
Viruses, Journal Year: 2023, Volume and Issue: 15(2), P. 400 - 400
Published: Jan. 31, 2023
A novel syndrome called long-haul COVID or long is increasingly recognized in a significant percentage of individuals within few months after infection with SARS-CoV-2. This disorder characterized by wide range persisting, returning even new but related symptoms that involve different tissues and organs, including respiratory, cardiac, vascular, gastrointestinal, musculo-skeletal, neurological, endocrine systemic. Some overlapping symptomatologies exist between myalgic encephalomyelitis/chronic fatigue (ME/CFS). Very much like ME/CFS, infections herpes family viruses, immune dysregulation, the persistence inflammation have been reported as most common pattern for development COVID. review describes several factors determinants proposed, elaborating mainly on viral persistence, reactivation latent viruses such Epstein–Barr virus human herpesvirus 6 which are also associated pathology superantigen activation system, disturbance gut microbiome, multiple tissue damage autoimmunity. Based these factors, we propose diagnostic strategies measurement IgG IgM antibodies against SARS-CoV-2, EBV, HHV-6, superantigens, microbiota, biomarkers autoimmunity to better understand manage this multi-factorial continues affect millions people world.
Language: Английский
Citations
81
Pharmacological Reports, Journal Year: 2021, Volume and Issue: 73(3), P. 736 - 749
Published: Jan. 3, 2021
COVID-19 cases are on surge; however, there is no efficient treatment or vaccine that can be used for its management. Numerous clinical trials being reviewed use of different drugs, biologics, and vaccines in COVID-19. A much empirical approach will to repurpose existing drugs which pharmacokinetic safety data available, because this facilitate the process drug development. The article discusses evidence available Ivermectin, an anti-parasitic with antiviral properties, rational review was carried out utilizing their clinically significant attributes. more thorough understanding met by virtual embodiment structure realizable viral targets using artificial intelligence (AI)-based molecular dynamics (MD)-simulation-based study. Certain studies have highlighted significance ivermectin COVID-19; it requires evidences from Randomised Controlled Trials (RCTs) dose- response support use. In silico-based analysis ivermectin's interaction specificity AI classical mechanics simulation-based methods indicates positive protein targets, leading SARS-CoV 2 N-protein NTD (nucleocapsid N-terminal domain).
Language: Английский
Citations
87
Future Virology, Journal Year: 2021, Volume and Issue: 16(4), P. 277 - 291
Published: March 25, 2021
Aim: COVID-19 is currently the biggest threat to mankind. Recently, ivermectin (a US FDA-approved antiparasitic drug) has been explored as an anti-SARS-CoV-2 agent. Herein, we have studied possible mechanism of action using in silico approaches. Materials & methods: Interaction against key proteins involved SARS-CoV-2 pathogenesis were investigated through molecular docking and dynamic simulation. Results: Ivermectin was found a blocker viral replicase, protease human TMPRSS2, which could be biophysical basis behind its antiviral efficiency. The ADMET profile on par with used anticorona drugs such hydroxychloroquine remdesivir. Conclusion: Our study enlightens candidature effective drug for treating COVID-19.
Language: Английский
Citations
69
Journal of Controlled Release, Journal Year: 2021, Volume and Issue: 341, P. 702 - 715
Published: Dec. 18, 2021
Language: Английский
Citations
66
Clinical Epidemiology and Global Health, Journal Year: 2021, Volume and Issue: 12, P. 100826 - 100826
Published: June 29, 2021
There is no specific antiviral treatment available for coronavirus disease 2019 (COVID-19). Among the possible natural constituents carrageenan, a polymer derived from marine algae that possesses variety of properties. The purpose this review was to summarize evidence supporting carrageenan subtypes' activity against emerging severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), causative agent COVID-19.PubMed/MEDLINE and Google Scholar searches were conducted publications using terms 'carrageenan', 'iota carrageenan', 'kappa lambda-carrageenan', 'coronavirus', 'common cold', 'rhinovirus', 'SARS-CoV-2' search also done in grey literature increase our understanding. A word "carrageenan" carried out. Most discussed narrative.Carrageenan has been shown have potent both coronaviruses (coronavirus NL63, SARS-CoV-2) non-coronaviruses such as dengue virus, herpes simplex cytomegalovirus, vaccinia vesicular stomatitis sindbis human immunodeficiency influenza papillomavirus, rabies junin tacaribe African swine fever, bovine suid rhinovirus. No vivo study an anti-SARS-CoV-2 agent. majority research on influenza, virus causes common cold together with coronavirus. Thus, various clinical trials determine transferability these vitro data effectiveness SARS-CoV-2. When combined oral ivermectin, nasally administered iota-carrageenan improved outcome COVID-19 patients. It still being tested clinics single-dose administration.Though exhibited SARS-CoV-2 used treat under emergency protocol conjunction medications there solid support its efficacy. are required assess efficacy prior broad application.
Language: Английский
Citations
65
Archives of Toxicology, Journal Year: 2021, Volume and Issue: 95(5), P. 1535 - 1546
Published: March 15, 2021
Language: Английский
Citations
47
Separation and Purification Technology, Journal Year: 2024, Volume and Issue: 350, P. 127955 - 127955
Published: May 14, 2024
Language: Английский
Citations
6
Drug Discovery Today, Journal Year: 2024, Volume and Issue: 29(7), P. 104026 - 104026
Published: May 17, 2024
Language: Английский
Citations
6
Environmental Science and Pollution Research, Journal Year: 2021, Volume and Issue: 28(18), P. 22241 - 22264
Published: March 18, 2021
Diseases negatively impact the environment, causing many health risks and spread of pollution hazards. A novel coronavirus, severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has led to a recent epidemic in humans. In December 2019, sudden emergence this new subsequent disease it causes created serious global threat This is contrast two aforementioned coronaviruses, SARS-CoV-2 (in 2002) middle east MERS-CoV 2012), which were much more easily contained. The World Health Organization (WHO) dubbed contagious an "epidemic outbreak" March 2020. More than 80 companies research institutions worldwide are working together, cooperation with governmental agencies, develop effective vaccine. To date, six authorized vaccines have been registered. Up till now, no approved drugs drug scientists racing from development clinical trials find for COVID-19. Wild animals, such as snakes, bats, pangolins main sources determined by sequence homology between viruses these animals. Human infection caused inhalation droplets. only available treatment protocol COVID-19 based on prevalent signs. review aims summarize current information regarding origin, evolution, genomic organization, epidemiology, molecular cellular characteristics well diagnostic approaches its health, economy.
Language: Английский
Citations
39
Journal of Controlled Release, Journal Year: 2021, Volume and Issue: 338, P. 813 - 836
Published: Aug. 31, 2021
Language: Английский
Citations
39